新诊断糖尿病患者门诊起始应用门冬胰岛素30的初步分析

摘要

目的 回顾性分析新诊断糖尿病患者门诊起始应用门冬胰岛素30治疗的特点.方法 比较41例新诊断糖尿病患者门冬胰岛素30每日2次或3次治疗3个月的使用特点.结果 每日2次门冬胰岛素30治疗组糖化血红蛋白(HbAlc)由基线(11.5±1.4)％下降至3个月后的(6.5±0.7)％；每日3次治疗组HbAlc由(12.5±1.4)％下降至(6.6±0.5)％,两组疗效相当.每日3次治疗组全日胰岛素最大用量[(0.48+0.09)U/(kg·d)]高于每日2次治疗组[(0.39±0.08) U/(kg·d)].每日2次治疗组有52％患者联合二甲双胍和(或)阿卡波糖.每日3次治疗组无人联合口服降糖药治疗.治疗期间两组分别有4例8次和3例3次发生低血糖,体重治疗后无明显变化.结论 新诊断高血糖的糖尿病患者在门诊起始应用门冬胰岛素30每日2次和每日3次治疗均能显著降低血糖,两组低血糖发生无差别.%Objective To demonstrate clinical features of biphasic insulin aspart 30 (BIAsp 30) in outpatients with newly diagnosed diabetes with hyperglycemia. Method Retrospectively, we analysed the records of 41 outpatients enrolled from March 2008 to July 2011 being initiated on either twice- (BID BIAsp 30) or thrice-daily (TID BIAsp 30) BIAsp 30. Result After 3 months treatment, there were no significant differences in glycosylated hemoglobin A1C (HbAlc) between the two therapies. [from baseline (11.5±1.4)% ,(12.5 ± 1.4)% to (6.5±0.7)% , (6.6±0. 5) % , respectively]. The maximal daily insulin doses were higher in TID BIAsp 30 group than in BID BIAsp 30 group [(0.48±0.09)U/(kg · d), (0. 39±0. 08) U/( kg · d), respectively] (P = 0. 003 ). In BID BIAsp 30 group, 52% patients combined with metformin and /or acarbose. None was in TID BIAsp 30 group. Eight episodes of hypoglycemia were reported in 4 subjects in BID BIAsp 30 group and in 3 patients with 3 times episodes in TID BIAsp 30 group. There was no significant difference in weight change. Conclusion Both BIAsp 30 BID and TID may significantly reduce blood glucose in outpatients with newly diagnosed diabetes. There is no difference in hypoglycemia.